You are here:
Direct Healthcare Professional Communication (Rote-Hand-Brief) on Accuzide of the company Pfizer: Recall due to nitrosamine contamination
2022.03.28
Active substance: Quinapril hydrochloride, hydrochlorothiazide
Pfizer informs about a precautionary recall of all strengths and package sizes of the medicinal product Accuzide at pharmacy level, as nitrosamine contamination has been detected by investigations. The recall will lead to shortages of Accuzide. At this time, no information can be given as to when the medicine will be available again. The investigations took place as part of the European risk assessment process initiated by the authorities and the EMA.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN